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Rae and coworkers \[[@B1]\] argued that there may be selection bias in our recently published study \[[@B2]\] and that, in fact, our findings are consistent with their previously reported data.

Our study (hereafter referred to as the \'current study\') \[[@B2]\] was conducted to validate whether polymorphisms in genes that encode metabolic enzymes may predict the response to tamoxifen among oestrogen receptor (ER)-positive postmenopausal breast cancer patients randomly assigned to treatment with or without tamoxifen. The initial trial was begun in 1976 in Stockholm, Sweden and patient material from approximately one-third of the initial population was available for use in the current study. In the Materials and method section of the report we compared characteristics such as lymph node status, ER status and tumour size between the initial and current study populations, and found that these parameters were similarly distributed throughout the populations. However, despite these similarities, selection bias could not be completely excluded, and this was noted in our conclusion, as was the need for confirmation of our findings in a larger randomized trial.

Initially, we assessed possible differences in prognostic value between genotypes of *CYP2D6*and *SULT1A1*in the study population (including both ER-negative and ER-positive patients). However, the primary aim was to investigate whether these genotypes could predict response to tamoxifen therapy in ER-positive patients. Strikingly, patients with different *CYP2D6*genotypes responded differently to therapy. We found no variation in distant recurrence-free survival among homozygous carriers of the *CYP2D6\*1*allele, but a significant difference was noted in carriers of the *CYP2D6\*4*allele. Recently, Nowell and coworkers \[[@B3]\] conducted a similar study in which they investigated the same *CYP2D6*polymorphism in patients either receiving or not receiving tamoxifen treatment. They found that the *CYP2D6\*4*variant allele appeared to be associated with decreases in death and recurrence rates. To our knowledge, no previous studies have been performed to elucidate the predictive value of *CYP2D6*genotypes on tamoxifen treatment.

Rae and colleagues \[[@B1]\] interpret our data as consistent with their findings, suggesting that *CYP2D6*poor metabolizers may derive less benefit from tamoxifen treatment. We disagree with that view. In support of their conclusion, Dr Rae and colleagues cite a meeting abstract of a study in which all patients were treated with tamoxifen and were not randomized according to tamoxifen treatment \[[@B4]\]. Our analysis represents a different comparison than that reported by Goetz and coworkers because, even though the sample population sizes are similar, result interpretation is highly dependent on randomization and study design. In our opinion we cannot endorse Dr. Rae\'s statement that our findings are consistent with their data.
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